SALT LAKE CITY, April 24 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals announced today the appointment of Juergen Lasowski, Ph.D., as senior vice president of corporate development, a new position. Dr. Lasowski will be responsible for the company’s corporate and business development efforts, including product and technology licensing, strategic acquisition efforts and corporate partnering activities worldwide. He joins NPS from Sanofi-Aventis (USA) where he was vice president of business development and strategy with responsibility for the development of licensing and commercial strategy activities in the United States. He previously had similar commercial responsibilities for North America with Aventis Pharmaceuticals and Hoechst Marion Roussel, and international management responsibilities with Hoechst AG.
“Juergen brings to NPS extensive pharmaceutical experience and strong corporate and business development skills that will be valuable to us as we work to leverage our product assets and generate revenues through corporate and product partnerships,” said Tony Coles, M.D., president and chief operating officer of NPS. “He joins an experienced business and commercial team and will play an important role in shaping and executing the NPS asset management strategy.”
About NPS Pharmaceuticals
NPS discovers, develops and commercializes small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has one FDA approved product, one product candidate undergoing regulatory review for approval to market in the U.S. and Europe, as well as other drug candidates in various stages of clinical development backed by a strong discovery research effort. Additional information is available on the company’s website, www.npsp.com.
Safe Harbor Statement
Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include: the FDA may delay approval or may not approve any of our product candidates; current collaborators or partners may not devote adequate resources to the development and commercialization of our licensed drug candidates which would prevent or delay introduction of drug candidates to the market; we may be unable to generate adequate sales and marketing capabilities to effectively market and sell our products; failure to secure adequate manufacturing and storage sources for our products could result in disruption or cessation of our clinical trials and eventual commercialization of such products; and, we may not have or be able to secure sufficient capital to fund development and commercialization of our product candidates. All information in this press release is as of April 24, 2006 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2005.
NPS Pharmaceuticals, Inc.
CONTACT: Brandi Simpson, Sr. Director, Investor Relations of NPSPharmaceuticals, Inc., +1-801-583-4939
Web site: http://www.npsp.com/
Company News On-Call: http://www.prnewswire.com/comp/613587.html /
